Clinical Documentation Improvement

Heterogeneous datasets are pervasive today, existing in various domains. Objects within these complex datasets are often represented from different perspectives, at different scales, or through multiple modalities, such as images, sensor readings, language sequences, and compact mathematical statements. Such datasets have been analyzed in the past using Multi-View Learning (MVL), Multi-Task Learning (MTL), and Tensor Learning (TL). In recent years, Multi-Modal Learning (MML) has also been employed. MML is a Machine Learning (ML) approach that integrates and processes information from multiple types of data, with different "perspectives" or "modalities" such as text, images, audio, video, or sensor data. The goal of MML is to leverage the complementary strengths of these modalities to improve model performance and enable richer understanding and predictions. Precision medicine and personalized clinical decision support systems (CDSS) tools have long aimed to leverage multimodal patient data to better capture complex, high-dimensional patient states and provider responses. This data ranges from free-form text notes and semi-structured electronic health records (EHR) to high-frequency physiological signals. While the advent of transformer architectures has enabled deeper insights from merging modalities, it has also required meticulous feature engineering and alignment. In patient monitoring, effectively analyzing diverse physiological signals within CDSS is highly challenging. #MedicalInformatics To address the challenges of analyzing multimodal patient data, the authors of [1] introduce MedTsLLM, a general multimodal large language model (LLM) framework that effectively integrates time series data and rich contextual information in the form of text. This framework performs three clinically relevant tasks (in time-series) which enable deeper analysis of physiological signals and can provide actionable insights for clinicians: • semantic segmentation • boundary detection • anomaly detection At a high level, boundary detection splits signals into periods like breaths or beats. Semantic segmentation further splits time series into distinct, meaningful segments. Anomaly detection identifies periods within the signals that deviate from normal. MedTsLLM utilizes a reprogramming layer to align embeddings of time series patches with a pretrained LLM's embedding space, making effective use of raw time series in conjunction with textual context. They additionally tailored the text prompt to include patient-specific information. Their experiments showed that MedTsLLM outperforms state-of-the-art baselines, including deep learning models, other LLMs, and clinical methods, across multiple medical domains, specifically electrocardiograms (ECG) and respiratory waveforms. Links to their preprint [1] and #Python GitHub repository [2] are shared in the comments.

Clinical Data Management Lifecycle: Ensuring Analysis-Ready, Regulatory-Grade Data Clinical Data Management is a structured process that converts raw clinical trial data into clean, consistent, and regulatory-compliant datasets for analysis, submissions, and patient safety. Phase 1 – Study Start-Up • Review protocol and identify study endpoints and required data points • Prepare Data Management Plan and Data Validation Plan • Design and annotate eCRFs aligned with the protocol • Build and configure the database in EDC/CDMS • Program edit checks and discrepancy rules • Set up MedDRA and WHO-Drug dictionaries for coding • Define external data transfer specs for labs, ECG, imaging, ePRO • Map CDISC standards and controlled terminology • Perform User Acceptance Testing and assign user roles • Align with eTMF and follow SOP-based workflows • Test integrations, randomization, and data flows Phase 2 – Study Conduct • Capture real-time data in EDC with source data alignment • Run automated and manual validation checks • Generate, track, and resolve queries with sites • Perform ongoing medical coding and coding reviews • Reconcile SAE data with the safety database • Reconcile lab, PK, imaging, and other external data • Support risk-based centralized data review • Implement protocol amendment changes in the database • Perform interim data cleaning and create data snapshots • Review listings, metrics, and quality dashboards Phase 3 – Study Close-Out • Complete final data cleaning and close all queries • Perform external data and SAE reconciliation sign-off • Conduct pre-lock quality control review • Freeze the database and then perform database lock • Extract SAS-ready datasets for biostatistics • Validate SDTM compliance for submission readiness • Support tables, listings, and figures for CSR • Review audit trails for inspection readiness • Archive data in validated systems with retention compliance Strong CDM processes ensure data integrity, GCP compliance, inspection readiness, and reliable clinical outcomes. This lifecycle highlights the collaboration between CRCs, CRAs, Clinical Data Coordinators, CDMs, and Biostatisticians in delivering high-quality clinical evidence. #ClinicalDataManagement #ClinicalResearch #ClinicalTrials #CDM #CRA #CRC #ClinicalDataCoordinator #ClinicalDataAssociate #ClinicalOperations #DataManagement #EDC #MedDRA #WHODrug #CDISC #SDTM #DatabaseLock #DataCleaning #QueryManagement #RiskBasedMonitoring #GCP #ICHGCP #Pharma #Biotech #DrugDevelopment #LifeSciences #ClinicalStudy #ResearchCareers #ClinicalResearchJobs #CRO #InspectionReadiness

Setting the Foundation for Healthcare Data Excellence 🏥 The Department of Health Abu Dhabi has released a comprehensive Data Architecture & Modeling Standard - a critical framework for transforming healthcare data management across the emirate's ecosystem. **Why This Matters:** In healthcare, inconsistent data interpretation can have serious consequences. This standard eliminates ambiguity by ensuring all stakeholders - from hospitals to insurers to research centers - speak the same data language. **Core Principles:** 🔗 **Integrated Ecosystem** - Seamless data flow across all platforms 🔒 **Secured by Design** - Compliance with ADHICS, PDPL, and UAE IA standards ✅ **Trustworthiness** - Reliable, accurate, transparent data handling 👥 **User-Centric** - Aligned with healthcare professionals' workflows 📈 **Scalable & Flexible** - Ready for growing data volumes and new technologies 🌐 **Federated by Design** - Decentralized management with centralized governance **Key Requirements:** - **Three-Layer Modeling**: Conceptual (business view) → Logical (function mapping) → Physical (implementation) - **Enterprise Data Model (EDM)**: Standardized representation across all master data - **Single Source of Truth (SSOT)**: Entity-level consistency extending to ecosystem-wide harmonization - **Data by Design**: Proactively identifying and capturing new data attributes - **Master Profiles**: Core operational data structures aligned across the ecosystem **Technical Highlights:** - Event-driven architecture standards - Unstructured data handling (using NLP, LLM when appropriate) - Modern metadata management with version control - Integration of structured and real-time streaming data **Governance Structure:** Clear RACI matrix with defined roles for Data Architects, Data Engineers, DDGO, and Cyber Security teams - ensuring accountability at every level. **The Impact:** ✓ Reduced reconciliation efforts ✓ Improved interoperability ✓ Enhanced data quality metrics ✓ Accelerated delivery through model reuse ✓ Measurable lineage coverage Effective April 2026, this standard represents a significant step toward unified, trustworthy healthcare data management in Abu Dhabi. #HealthcareData #DataArchitecture #DataGovernance #DigitalHealth #HealthIT #AbuDhabi #DataStandards #Healthcare #DigitalTransformation

Post#115: Fast-Track Protocol Interpretation: A CDM’s Go-To Checklist . . . . As Clinical Data Managers (CDMs), accurately interpreting the clinical trial protocol is crucial. A misinterpretation can lead to data gaps, costly amendments, and regulatory risks. To help, here’s a structured checklist to ensure CDMs extract key protocol details from Study Startup to Closeout. 📌 Let’s dive in! ⬇️ 1️⃣ Study Background, Objectives & Endpoints ✔️ What therapeutic area and disease is the study focused on? ✔️ What are the standard treatments available in the market? ✔️What are the primary & secondary endpoints, and how are they measured? 2️⃣ Study Design & Randomization ✔️ What’s the study type? (Randomized, open-label, placebo-controlled, adaptive?) ✔️ How is randomization structured (block sizes, stratification factors, IRT)? ✔️ Does the protocol include adaptive elements (e.g., dose escalation, cohort expansion)? ✔️ How does blinding impact data access and unblinding? 3️⃣ Eligibility Criteria & Protocol Deviations ✔️ What are the key inclusion & exclusion criterias? ✔️ How will protocol deviations be captured and categorized (major vs. minor)? 4️⃣ Study Visits, Assessments & Data Collection ✔️ What are the visit schedules and window constraints? ✔️ Are there conditional assessments (e.g., AE-driven follow-ups)? ✔️ How will unscheduled visits be captured in the EDC? 5️⃣ Safety Reporting & Medical Monitoring ✔️ What are the AE, SAE, and SUSAR reporting requirements? ✔️ How does safety data flow between EDC, PV teams, and regulatory bodies? ✔️ Are there DMC/DSMB reviews, and how will safety signals be tracked? 6️⃣ External Data Sources & Vendor Management ✔️ What external data sources are used (e.g., central labs, ECG, ePRO, wearables)? ✔️ What’s the data transfer frequency, and how is reconciliation handled? 7️⃣ Medical Coding & Terminology Standards ✔️ Are AEs coded with MedDRA, and how are discrepancies resolved? ✔️ Is WHO Drug Dictionary coding required for concomitant medications? 8️⃣ Study Milestones, Interim Analyses & Data Cutoffs ✔️ What are the critical study phases (e.g., FPI, LPI, LPLV, DBL)? ✔️ Are interim analyses planned, and how will data be locked for them? ✔️ What are the regulatory submission deadlines impacting DBL? 9️⃣Study Finance & Budget Considerations  ✔️What is the budget allocation for data management activities (e.g., EDC build, data cleaning, coding, integrations)? ✔️Are there any cost implications for database amendments or protocol deviations? what other pointers you will add?? #clinicaldatamanagement #clinicalresearch #clinicaltrials

This paper proposes structured guidance for how healthcare teams should manage and use patient-generated health data (PGHD) in clinical settings. 1️⃣ PGHD—data from health apps and devices—has shown promise for improving outcomes but raises concerns about integration, data quality, legal liability, and clinical workflows. 2️⃣ A team at Stanford Medicine developed four guiding principles through iterative focus groups involving clinicians, compliance experts, and IT leaders. 3️⃣ The principles stress: setting clear expectations with patients, preparing clinic workflows and staffing, ensuring high-quality tech experiences, and addressing data security and record-keeping. 4️⃣ PGHD includes both solicited data (requested by clinicians) and unsolicited data (shared by patients), each requiring different handling strategies. 5️⃣ Clinicians want EHRs to show trends instead of raw data points, and they favor alert systems to identify abnormal values efficiently. 6️⃣ High-risk data requires clear escalation pathways; clinicians cautioned against relying solely on automated systems to flag urgent issues. 7️⃣ PGHD should be stored for as long as standard medical records (7 years), and placement in or outside the official medical record depends on how it informs care. 8️⃣ Participants emphasized the need for patient education and documentation of consent regarding how their data is used and reviewed. 9️⃣ Global standards like FHIR are supporting PGHD interoperability, with 23 countries adopting relevant data exchange regulations. 🔟 Final recommendations include annual reviews of the guidance and distributing simplified summaries to ensure organization-wide adoption. ✍🏻 Ashley Griffin, Megan Moyer, Arash Anoshiravani, Sondra Hornsey, Christopher Sharp. A sociotechnical approach to defining clinical responsibilities for patient-generated health data. npj Digital Medicine. 2025. DOI: 10.1038/s41746-025-01680-5

Biostatisticians at the Mercy of Clinical Data Management: The Quiet Truth No One Likes to Say Out Loud Biostatisticians are known for many things: Clear thinking. Scientific judgment. Grace under pressure. Occasional “Friday afternoon miracles.” But here’s one thing we don’t talk about enough: 👉 Biostatisticians are often completely at the mercy of Clinical Data Management. And I say this with love — because when CDM is strong, a trial hums. When CDM is stretched, understaffed, rushed, or fragmented… the ripple hits everyone. But the final wave almost always lands on the biostatistician’s desk. Here’s what that looks like in real life: Database delays that compress the entire analysis timeline Query backlogs that suddenly become “statistical issues” Mid-study specification changes that rewrite half the SAP Inconsistent coding that shows up during safety reconciliation Data freezes that thaw unexpectedly (“just one more batch…”) Missing forms that magically become the statistician’s problem A database lock that isn’t really locked (you know the type) And somehow, despite all of this, the expectation remains: “Stats will figure it out.” Here’s the secret no one tells junior biostatisticians: 📌 You can be brilliant, prepared, organized, and proactive… and still be completely limited by the quality, stability, and timeliness of the data management function. Because biostatistics is the last stop before results, the first group blamed when timelines slip, and the only group expected to fix everything downstream — even when the upstream issues were out of their control. But here’s the good news: The trials that run smoothly do so because CDM and Biostats operate as partners, not strangers. Early alignment solves 80% of the crises we see at the end. ✨ Data Management defines the structure. ✨ Biostatistics defines the meaning. ✨ Together, they define the science. When those two groups stay connected — really connected — everything from protocol design to database lock to final analysis becomes safer, faster, and more reliable. My message to every team I mentor: Stats and CDM don’t need more heroics. They need earlier collaboration and shared ownership. Because biostatisticians can do a lot. But even we can’t analyze data that isn’t clean, coded, harmonized, or ready. And honestly? We shouldn’t be asked to.

Post 1 of my #FromDatatoDecisions series Most AI initiatives in clinical data management start in the wrong place. Before you deploy a data mapping agent, a review agent, or any predictive model you need to ask a harder question: can your data infrastructure actually support AI, or are you building on sand? In the first post of my new series From Data to Decisions: The #AI #Agent Revolution in #ClinicalDataIntelligence, I make the case that the biggest barrier to AI in clinical trials isn't technology. It's architecture. Fragmented systems. Manual consolidation. #SDTM standardization happening at submission time instead of ingestion. These aren't IT problems, they're strategic liabilities that determine whether your AI investments deliver or disappoint. The post includes a three-stage maturity model and five diagnostic questions to assess where your organization actually stands before your next AI conversation.

Everyone talks about Clinical Data Strategy for the AI era, but has anyone talked about what it is? Here is a blueprint. Your clinical trial is generating genomic files, wearable telemetry, DICOM images, and eCRF entries simultaneously. Your relational database was designed for none of this. The gap between the data you're generating and the data you can actually use is costing you approvals. Consider the scale we're actually dealing with: • Genomic data in public repositories grew from 47 GB in 2007 to 28 petabytes by 2024. • A 620,000-fold increase in less than 20 years. • Modern wearable DHT pipelines can generate up to 48,000 records per second. • Your legacy data warehouse was not designed for any of this. The future-ready clinical platform requires a 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 𝐋𝐚𝐤𝐞𝐡𝐨𝐮𝐬𝐞 — a hybrid architecture that merges the scalability of a data lake with the ACID transaction guarantees and governance of a traditional warehouse. The Medallion Architecture in clinical practice: 🥉 Bronze Layer Raw, unstructured ingestion — JSON from wearables, DICOM, raw EHR Bioinformatics  End Users: Engineers, data scientists, algorithm training 🥈 Silver Layer Cleansed, conformed data — normalized, harmonized to CDASH/FHIR End Users: Data managers, biostatisticians for exploratory analysis 🥇 Gold Layer Submission-ready CDISC SDTM/ADaM datasets — fully validated, governed End Users: Regulators, clinical monitors, medical writers — the only layer for submission Additionally, this architecture addresses the RWE interoperability problem as well. Clinical trial data lives in CDISC SDTM. Real-world data lives in OMOP, PCORnet, or HL7 FHIR. These worlds have never automatically translated. Native FHIR-to-SDTM mapping, anchored by semantic sources of truth like the NCI caDSR, finally enables continuous, automated ETL of EHR data directly into regulatory-compliant formats. The practical result: sponsors can now track long-term patient safety post-trial, validate clinical outcomes, and monitor for adverse events extending years beyond formal study closeout — all while maintaining cryptographic privacy compliance. 𝐀𝐫𝐜𝐡𝐢𝐭𝐞𝐜𝐭𝐮𝐫𝐞 𝐢𝐬𝐧'𝐭 𝐚𝐧 𝐈𝐓 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐚𝐧𝐲𝐦𝐨𝐫𝐞. 𝐈𝐭'𝐬 𝐚 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲. If you're a technology vendor, investor, or sponsor, please reach out to discuss how to build a solid data foundation that is tailor-made for your needs. #DataLakehouse #ClinicalData #CDISC #FHIR #RealWorldEvidence #DataEngineering #LifeSciences #Databricks #Snowflake #HealthcareData #DigitalHealth #ClinicalTrials #BioTech #Pharma #HL7 #Microsoft

As data management evolves in healthcare and life sciences, clinical expertise is becoming crucial in assessing data quality anomalies and ensuring the accuracy and relevance of data. By leveraging clinical insights, data management systems can go beyond technical validations to more nuanced, clinically meaningful evaluations. This trend is enhancing the way organizations manage data related to treatment regimens, patient pathways, and outcomes. Let us look at how the clinical expertise enhances Data Quality Management: Contextual Understanding of Anomalies: Clinical experts can differentiate between real data anomalies and acceptable clinical variances, ensuring that flagged issues reflect genuine concerns rather than natural clinical variations. As an example: A spike in blood pressure might not be an anomaly but a known side effect of a treatment regimen. Validation of Complex Treatment Pathways: Experts can verify that complex treatment pathways are accurately reflected in data, ensuring outcomes match clinical reality. In oncology, clinical experts can ensure that drug sequences and combinations are captured correctly. Reducing False Positives: Clinical insights can help minimize false positives by distinguishing normal clinical variations from real data quality issues, reducing unnecessary investigations. As an example, experts know lab values can fluctuate based on time of day, preventing unnecessary alerts. Enhanced Anomaly Detection: Clinical experts can help refine machine learning models, improving their ability to detect significant data quality issues. Experts can train models to recognize drug interactions or side effects that may cause data deviations. Deeper Insights into Patient Pathways: Clinical experts can interpret data within the context of patient care journeys, leading to better insights into treatment efficacy. As an example: Experts may see changes in a medication regimen as an indicator of disease progression. Optimized Data Stewardship: Clinical insights can guide data stewards to focus on issues that affect patient care, rather than irrelevant data points. In rare diseases, clinical experts help prioritize quality issues affecting treatment efficacy. As can be seen above, integrating clinical experts into data management processes can add a critical layer of expertise that enhances data accuracy, reduces false positives, and provides more relevant insights into patient care. This collaboration has the potential to significantly improve data quality, leading to better healthcare outcomes and more informed decisions.